Therapeutic Antibody Lead Discovery
Therapeutic antibody lead discovery involves the selection of antibody candidates for targeted therapies. After a specific target has been identified, antibodies are produced using the target molecule as an antigen. Antibodies can be generated using methods including hybridoma technology, B cell cloning, and phage display. Antibodies are then purified and screened for their ability to bind antigen. Selected antibodies are further characterized to determine their specificity, affinity, stability, and pharmacokinetic properties. We provide numerous platforms and reagents to support the lead discovery process, from monoclonal antibody generation to isolation, selection, and lead optimization.
Monoclonal Antibody Production and Purification
Major technological advances have made the production of monoclonal antibodies quicker and more efficient. There are three established platforms for antibody discovery: hybridoma development, B cell cloning, and antibody phage display. We offer reagents for production of monoclonal antibody libraries using each of these techniques.
Our antibody isolation and purification solutions are designed to support rapid and efficient sample preparation. Our advanced technology and extensive expertise in sample preparation allow you to move quickly and efficiently to the next step in the lead discovery process.
Hybridoma Development
Hybridoma technology is the most-widely recognized immortalization technique of mouse B cells and has revolutionized monoclonal antibody (mAb) discovery. This technique begins with the immunization of animals with target antigen to elicit an immune response and initiate B cell maturation. B cells are then isolated and fused with myeloma tumor cells to generate hybridomas. Because every B cell produces a unique antibody, single-cell cloning of hybridomas can be used to generate libraries of monoclonal antibodies on a large scale. Antibodies are then isolated or purified from the supernatant of cultured hybridoma cells. This technique is well-established and produces highly pure and specific antibodies.
Our hybridoma development tools were designed to streamline the hybridoma fusion and screening process to maximize efficiency. We carry a selection of products ranging from fusion cell lines to cell culture media, growth factors, and antibiotics.
B Cell Cloning
B cell cloning is a newer, powerful technique used to generate monoclonal antibodies without the need to immortalize selected antibody-secreting cells (ASCs). These cells are screened and isolated directly from peripheral blood or lymphoid tissue samples. Immunoglobulin gene amplification is then used to clone the full-length immunoglobulin genes (variable and constant regions of the light and heavy chains) for recombinant expression in cell culture. One main advantage of single B cell cloning is the ability to isolate neutralizing mAbs from vaccinated or naturally immunized human subjects for cloning.
Single B cell technologies have significantly evolved, with faster processing times and higher throughput capacity. Our cutting-edge tools support the B cell cloning process.
Antibody Phage Display
Antibody phage display has been widely used for the generation of recombinant monoclonal antibody libraries. This technique relies on the ability of bacteriophages to display peptides of interest on their surface following the insertion of DNA fragments into the filamentous phage coat protein gene. Libraries of human-derived mAbs can be isolated from large Ig gene repertoires displayed on the surface of phages. Purified antigen can then be used to pan for high affinity, target-specific antibodies.
Antibody phage display is a robust and cost-effective technology that enables identification of fully human-derived, high-affinity mAbs. Streamline monoclonal antibody production and screening with our suite of phage display tools.
Categorías relacionadas
A broad range of chromatography tools for antibody purification.
Artículos relacionados
- Hybridoma Fusion Partner Cell Lines
Choose from dozens of options to find the optimal fusion partner and increase the efficiency of hybridoma growth and antibody synthesis.
Explore our Products & Services
Para seguir leyendo, inicie sesión o cree una cuenta.
¿No tiene una cuenta?